Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018/01/10 by Michael A. Postow, Robert Sidlow, Matthew D. Hellmann · 4,775 citations
Immunology and Microbiology · Medicine · #Adverse effect #Blockade #Cancer Immunotherapy and Biomarkers #Colorectal Cancer Treatments and Studies #Immune Cell Function and Interaction #Immune checkpoint #Immune system #Immunology #Immunotherapy #Internal medicine #Medicine #Receptor
paper · doi:10.1056/nejmra1703481
published in New England Journal of Medicine 378(2), 158-168 (Massachusetts Medical Society)
openalex publication_date 2018/01/10 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
Abstract
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.
Citations
Cited by
- Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort
- Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
- Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis
- Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
- Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- Polymer-based hydrogels with local drug release for cancer immunotherapy
- IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis
- The Future of Personalized Cancer Vaccines
- Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
- Checkpoint inhibitors create rogue regulatory T cells
- Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
- Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses
- Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling
- Gut Microbiota–Related Biomarkers in Immuno-Oncology
- A Field Guide to Deploying AI Agents in Clinical Practice
- Immune checkpoint inhibitors and acute kidney injury
- Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
- Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks
- Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response
- Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer
- Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors
- Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
- Incidence risk of PD-1/PD-L1–related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials
- Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
- Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers
- Orai1- and STIM1-mediated calcium signaling controls PD-L1 expression and modulates antitumor immunity in oral cancer
- Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis
- The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency
- A guide to cancer immunotherapy: from T cell basic science to clinical practice
- PET/CT in Inflammatory and Auto-immune Disorders: Focus on Several Key Molecular Concepts, FDG, and Radiolabeled Probe Perspectives
- From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)
- Factors associated with immune-related adverse events in cancer patients treated with immunotherapy visiting the emergency department
- Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice
- Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
- Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy
- Cancer immunotherapy using checkpoint blockade. [europepmc]
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. [europepmc]
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. [europepmc]
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. [europepmc]
- Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. [europepmc]
- Immune checkpoint inhibitors: recent progress and potential biomarkers. [europepmc]
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. [europepmc]
- The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. [europepmc]
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. [europepmc]
- Enhancing cancer immunotherapy with nanomedicine. [europepmc]
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. [europepmc]
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. [europepmc]
- Immune-related adverse events of checkpoint inhibitors. [europepmc]
- A guide to cancer immunotherapy: from T cell basic science to clinical practice. [europepmc]
- Immune checkpoint signaling and cancer immunotherapy. [europepmc]
- Targeted therapy for hepatocellular carcinoma. [europepmc]
- Recent advances and discoveries in the mechanisms and functions of CAR T cells. [europepmc]
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. [europepmc]
- Next generation of immune checkpoint inhibitors and beyond. [europepmc]
- Advances in immunotherapy for hepatocellular carcinoma. [europepmc]
- Translational Applications of Hydrogels. [europepmc]
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. [europepmc]
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. [europepmc]
- Immune-checkpoint inhibitors: long-term implications of toxicity. [europepmc]
- The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. [europepmc]
Related